Scanning electron microscopy visualization of methicillin-resistant staphylococcus aureus after contact with gatifloxacin with and without preservative

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 2, 2010, Pages 133-136

  Monson, Bryan K ^a   Stringham, Jack ^a   Jones, Brandt B ^a   Abdel Aziz, Salwa ^a   Cutler Peck, Carolee M ^a   Olson, Randall J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN;

ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SCANNING ELECTROCHEMICAL MICROSCOPY;

FLUOROQUINOLONES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROSCOPY, ELECTRON, SCANNING; PRESERVATIVES, PHARMACEUTICAL;

EID: 77951671762     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0108     Document Type: Article

References (26)

1. Asbell, P. A., Colby, K. A., Deng, S., et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am. J. Ophthalmol. 145: 951-958, 2008.
2. Blondeau, J. M., Borsos, S., and Hesj e, C. K. Antimicrobial effi cacy of gatifl oxacin and moxifl oxacin with and without benzalkonium chloride compared with ciprofl oxacin and levofl oxacin against methicillin-resistant Staphylococcus aureus. J. Chemother. 19: 146-151, 2007.
3. Han, D. P., Wisniewski, S. R., Wilson, L. A., et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am. J. Ophthalmol. 122: 1-17, 1996. (Pubitemid 26230889)
4. Kowalski, R. P., and Dhaliwal, D. K. Ocular bacterial infections: current and future treatment options. Expert Rev. Anti Infect. Ther. 3: 131-139, 2005. (Pubitemid 40277844)
5. Tazawa, H., and Ooishi, M (Pubitemid 20204025)
6. Shanmuganathan, V (Pubitemid 40484821)
7. Blomquist, P.H. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 104: 322-345, 2006.
8. Cavuoto, K., Zutshi, D., Karp, C (Pubitemid 350309422)
9. Fridkin, S.K., Hageman, J.C., Morrison, M., et al. Methicillinresistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352: 1436-1444, 2005. (Pubitemid 40471451)
10. Rutar, T., Chambers, H (Pubitemid 44108175)
11. Solomon, R., Donnenfeld, E.D., Perry, H.D., et al. Methicillinresistant Staphylococcus aureus infectious keratitis following refractive surgery. Am. J. Ophthalmol. 143: 629-634, 2007. (Pubitemid 46463939)
12. Fiscella, R. G., Lewis, C. C., and Jensen, M. K. Topical ophthalmic fourth-generation fl uoroquinolones: appropriate use and cost considerations. Am. J. Health Syst. Pharm. 64: 2069-2073, 2007.
13. Mah, F. S. Fourth-generation fl uoroquinolones: new topical agents in the war on ocular bacterial infections. Curr. Opin. Ophthalmol. 15: 316-320, 2004.
14. Tepedino, M. E., Heller, W. H., Usner, D. W., et al. Phase III effi-cacy and safety study of besifl oxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr. Med. Res. Opin. 25: 1159-1169, 2009.
15. Sanders, M. E., Norcross, E. W., Moore, Q. C., III, et al. Effi cacy of besifl oxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. Cornea. 28: 1055-1060, 2009.
16. McDonald, M. B., Protzko, E. E., Brunner, L. S., et al. Effi cacy and safety of besifl oxacin ophthalmic suspension 0.6% compared with moxifl oxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 116: 1615-1623 e1, 2009.
17. Haas, W., Pillar, C. M., Zurenko, G. E., et al. Besifl oxacin, a novel fl uoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 53: 3552-3560, 2009.
18. Zhang, J. Z., and Ward, K. W. Besifl oxacin, a novel fl uoroquinolone antimicrobial agent, exhibits potent inhibition of pro-infl ammatory cytokines in human THP-1 monocytes. J. Antimicrob. Chemother. 61: 111-116, 2008. Zymar [package insert]. Irvine CA: Allergan Inc. 2004. Zymar [package insert]. Irvine, CA: Allergan, Inc., 2004.
19. Friedlaender, M. H., Breshears, D., Amoozgar, B., et al. The dilution of benzalkonium chloride (BAK) in the tear fi lm. Adv. Ther. 23: 835-841, 2006. (Pubitemid 46341041)
20. Olson, R. Zymar as an ocular therapeutic agent. Int. Ophthalmol. Clin. 46: 73-84, 2006. (Pubitemid 44632210)
21. Kowalski, R. P., Kowalski, B. R., Romanowski, E. G., et al. The in vitro impact of moxifl oxacin and gatifl oxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial effi cacy. Am. J. Ophthalmol. 142: 730-735, 2006.
22. Romanowski, E. G., Mah, F. S., Kowalski, R. P., et al. Benzalkonium chloride enhances the antibacterial effi cacy of gatifl oxacin in an experimental rabbit model of intrastromal keratitis. J. Ocul. Pharmacol. Ther. 24: 380-384, 2008.
23. Dantas, P. E., Uesugui, E., Nishiwaki-Dantas, M. C., et al. Antibacterial activity of anesthetic solutions and preservatives: an in vitro comparative study. Cornea. 19: 353-354, 2000 (Pubitemid 30322463)
24. Hesj e, C. K., Borsos, S. D., and Blondeau, J. M. Benzalkonium chloride enhances antibacterial activity of gatifl oxacin and reduces its propensity to select for fl uoroquinolone-resistant strains. J. Ocul. Pharmacol. Ther. 25: 329-334, 2009.
25. Romanowski, E. G., Mah, F. S., Yates, K. A., et al. The successful treatment of gatifl oxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifl oxacin 0.3%) in a NZW rabbit model. Am. J. Ophthalmol. 139: 867-877, 2005.
26. Tungsiripat, T., Sarayba, M. A., Kaufman, M. B., et al. Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. Am. J. Ophthalmol. 136: 76-81, 2003. (Pubitemid 36794498)